2023 Was a tricky year for the biopharma market, with many businesses downsizing and restructuring their workforces to stay afloat. There are actually signs of recovery, as mergers and acquisitions picked up through the pharmaceutical and existence sciences sector during the latter A part of 2023 and also have continued https://sites.google.com/view/bio-sites/blog